Pharmaids Pharmaceuticals Ltd
Incorporated in 1989, Pharmaids Pharmaceuticals Ltd manufactures Bulk Drugs and Intermediaries.
- Market Cap ₹ 166 Cr.
- Current Price ₹ 47.0
- High / Low ₹ 85.0 / 42.0
- Stock P/E
- Book Value ₹ 16.4
- Dividend Yield 0.00 %
- ROCE -6.87 %
- ROE -10.8 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.86 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 33.0%
- Company has a low return on equity of -15.3% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 2 | 1 | 0 | 1 | 0 | 9 | 4 | 0 | 0 | 2 | 8 | |
| 2 | 2 | 2 | 2 | 1 | 1 | 0 | 8 | 4 | 10 | 6 | 10 | 22 | |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | -10 | -6 | -7 | -14 |
| OPM % | -32% | -5% | -21% | -28% | -87% | -20% | 1% | 3% | -21,267% | -310% | -165% | ||
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 5 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0 | -0 | -0 | 0 | -0 | -0 | -0 | 0 | 0 | -10 | -6 | -9 | -14 |
| Tax % | -3% | -36% | -7% | -33% | 5% | 20% | -108% | 0% | 0% | -24% | -19% | -15% | |
| -0 | -0 | -0 | 0 | -0 | -0 | 0 | 0 | 0 | -8 | -5 | -7 | -11 | |
| EPS in Rs | -1.03 | -0.21 | -1.17 | 0.32 | -1.15 | -0.53 | 0.03 | 0.09 | 0.15 | -3.52 | -1.40 | -2.06 | -3.03 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | % |
| 3 Years: | -16% |
| TTM: | 718% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -129% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 30% |
| 3 Years: | 54% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -13% |
| 3 Years: | -15% |
| Last Year: | -11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 10 | 21 | 35 | 35 | 35 |
| Reserves | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | 1 | 36 | 29 | 23 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 40 | 18 | |
| 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 15 | 21 | |
| Total Liabilities | 3 | 3 | 2 | 2 | 1 | 9 | 8 | 9 | 11 | 25 | 85 | 119 | 97 |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 24 | 8 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 4 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 53 | 53 | 53 |
| 2 | 2 | 2 | 2 | 1 | 8 | 8 | 9 | 11 | 19 | 14 | 38 | 33 | |
| Total Assets | 3 | 3 | 2 | 2 | 1 | 9 | 8 | 9 | 11 | 25 | 85 | 119 | 97 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | -0 | -0 | -1 | 0 | -0 | -4 | -3 | -8 | |
| 0 | -0 | -0 | 0 | -0 | 0 | 1 | -0 | 0 | -5 | -73 | -19 | |
| -0 | -0 | 0 | -0 | -0 | -0 | 0 | 0 | 0 | 21 | 66 | 25 | |
| Net Cash Flow | -0 | 0 | -0 | 0 | -0 | -0 | -0 | 0 | 0 | 12 | -10 | -2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 331 | 234 | 232 | 240 | 422 | 580 | 12 | 124 | 0 | 25 | ||
| Inventory Days | 104 | 103 | 91 | 131 | 0 | 0 | 17 | 91 | 0 | 4,198 | 1,774 | |
| Days Payable | 197 | 145 | 138 | 245 | 22 | 236 | 0 | 2,067 | ||||
| Cash Conversion Cycle | 238 | 192 | 185 | 126 | 422 | 580 | 6 | -21 | 4,198 | -267 | ||
| Working Capital Days | 244 | 181 | 148 | 161 | 227 | 2,653 | 3 | -18 | 14,600 | -471 | ||
| ROCE % | -15% | -5% | -21% | -24% | -30% | -3% | -5% | 1% | 2% | -64% | -11% | -7% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Nov - Newspaper Publication of unaudited Financial Results (Consolidated and Standalone) for the Quarter and Half Year Ended September 30, 2025
-
Re-Lodgement Of Requests For Transfer Of Physical Shares
12 Nov - RTA reports zero re-lodged physical share transfer requests as of 5 Nov 2025 under SEBI window.
-
Board Meeting Outcome for Outcome Of The Board Meeting
11 Nov - Approved unaudited standalone & consolidated Q2/H1 financial results and limited review report for September 30, 2025.
-
Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2025.
11 Nov - Board approved unaudited standalone and consolidated results with limited review for quarter and H1 ended Sept 30, 2025.
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2025.
6 Nov - Board meeting Nov 11, 2025 to approve unaudited Q2/H1 results (Sept 30, 2025); trading window closed until 48 hours post-declaration.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Product Portfolio:
a) Specialty Chemicals:[1] Retinol, DL Alpha Tocopherol, D-Pantothenate, Cyanocobalamin, Pyridoxine Hcl, Thiamine, Nicotinic Acid, Water Sol. Vitamin E, Coenzyme Q10, D-Biotin
b) Skin Care:[2] Best care hands, Hands Sanitizer, Moisturizing Cream, Skin-Sure Plus, Skin-Sure Ultra, Alcohol Gel, Barrier Cream
c) Hospital Care:[3] Xepi Rub M, Facein Spray, Sod Hypochlorite, Sanmedin, Strumen-G, Strumen TRIACID, Facein Eco, Facein Power, Facein Spray, Sod Hypochlorite, Wipes, PPE
d) Generics:[4] Linzomust, Ceforoot 1.5g, Trendyclav-L, Cobasure Gold 2ML INJ, Benfoshine, Amplimmune, Thiaxa T8, Molprime SR, Citibrain-Plus, Duojoint